Abstract:Abstract Background Gut microbiomes are altered among patients with IBD. Certain microbiome species were used as biomarkers for IBD diagnosis, yet with limited sensitivity and specificity, especially when used for the classification of UC and CD. Gut microbiome reprogramming was accompanied with metabolic shift. Previous studies discovered that gut microbiome-associated serum metabolites (GMSM) were disease-specific biomarkers with high sensitivity. The aim of this study is to explore how gut microbiome reprogramming is reflected in serum metabolome shift in IBD, and the potential of GMSM for IBD diagnosis and classification of UC and CD. Methods Shotgun metagenomic of stool and ultraperformance liquid chromatography-mass spectrometry based untargeted metabolomic profiling of serum samples from a discovery cohort of IBD and healthy individuals were performed. Spearman correlation analysis was used to identify GMSM that were differentially abundant among IBD and healthy individuals. Candidate GMSM for model construction were selected using LASSO and logistic regression. The selected GMSM panel was then transferred to multiple reaction monitoring based targeted detection. Diagnostic model for IBD and classification model for UC and CD were developed based on the GMSM panel using a training cohort, and then validated using an independent cohort consisting of patients with IBD, healthy individuals and patients with colorectal adenoma or non-adenoma polyps. Results Metagenome sequencing of fecal samples from 77 patients with IBD and 74 healthy individuals revealed significant shifts in gut microbiome, such as decrease in F. prausnitzii. Untargeted metabolomic profiling of serum from 76 patients with IBD and 28 healthy individuals revealed 724 differentially abundant metabolites, of which 151 metabolites were found to be significantly associated with gut microbiomes detected from the fecal samples (figure). Candidate GMSM for model construction were established using the method described and the ultimate panel consisted of 17 metabolites, including 10 GMSM for diagnostic model for IBD and 7 GMSM for classification model for UC and CD. Eventually, the diagnostic model for IBD achieved an area under curve (AUC) of 0.98 in the training cohort, and 0.92 in the validation cohort. The classification model for UC and CD achieved AUC of 0.94 in the training cohort, and 0.9 in the validation cohort. In addition, the diagnostic model for IBD also effectively distinguished IBD from patients with colorectal adenoma or non-adenoma polyps (table). Conclusion Based on GMSM, we developed diagnostic and classification models for IBD with high specificity and sensitivity, providing an accurate and non-invasive approach for IBD diagnosis and classification of UC and CD.

Metabonomics Study of Intestinal Fistulas Based on Ultraperformance Liquid Chromatography Coupled with Q-TOF Mass Spectrometry (UPLC/Q-TOF MS)

A serum metabonomics study on drug induced liver injury by UPLC coupled with Q-TOF mass spectrometry

Metabolomic analyses of faeces reveals malabsorption in cirrhotic patients.

Fecal Metabolome Profiling of Liver Cirrhosis and Hepatocellular Carcinoma Patients by Ultra Performance Liquid Chromatography–mass Spectrometry

Serum metabolite profiling of human colorectal cancer using GC-TOFMS and UPLC-QTOFMS.

High performance liquid chromatography-mass spectrometry for metabonomics: potential biomarkers for acute deterioration of liver function in chronic hepatitis B.

Metabolite profiling of plasma and urine from rats with TNBS-induced acute colitis using UPLC-ESI-QTOF-MS-based metabonomics--a pilot study.

Application of faecal metabonomics on an experimental model of tubulointerstitial fibrosis by ultra performance liquid chromatography/high- sensitivity mass spectrometry with MSE data collection technique

Development of High-Performance Chemical Isotope Labeling LC-MS for Profiling the Human Fecal Metabolome.

A Strategy for the Targeted Metabolomics Analysis of 11 Gut Microbiota-Host Co-Metabolites in Rat Serum, Urine and Feces by Ultra High Performance Liquid Chromatography–tandem Mass Spectrometry

Targeted UPLC-MS Metabolic Analysis of Human Faeces Reveals Novel Low-Invasive Candidate Markers for Colorectal Cancer

Identification of Bile Biomarkers of Biliary Tract Cancer Through A Liquid Chromatography/Mass Spectrometry-Based Metabolomic Method

Metabonomics Study of Urine Samples of Patients with Hyperlipidemic Pancreatitis

A metabonomic study of hepatitis B-induced liver cirrhosis and hepatocellular carcinoma by using RP-LC and HILIC coupled with mass spectrometry.

UPLC-QTOF-MS-Based Plasma Lipidomic Profiling Reveals Biomarkers for Inflammatory Bowel Disease Diagnosis.

Development of an Efficient and Sensitive Chemical Derivatization-Based LC-MS/MS Method for Quantifying Gut Microbiota-Derived Metabolites in Human Plasma and Its Application in Studying Cardiovascular Disease

A Landscape of Metabonomics for Intermingled Phlegm and Blood Stasis and Its Concurrent Syndromes in Stable Angina Pectoris of Coronary Heart Disease

P380 Integrated fecal metagenome and serum metabolome analysis revealed gut microbiome associated serum metabolites as diagnostic biomarkers for inflammatory bowel disease

Strategy for characterization and quantification of fatty acids in plasma by parallel d 0 /d 6 -dansylhydrazine derivatization combined with UPLC–MS/MS

Exploratory urinary metabolic biomarkers and pathways using UPLC-Q-TOF-HDMS coupled with pattern recognition approach

Lysophosphatidylcholine Biomarkers of Lung Cancer Detected by Ultra-Performance Liquid Chromatography Coupled with Quadrupole Time-Of-Flight Mass Spectrometry